An advanced-clinical-stage biotechnology company developing dendritic cell therapies to treat cancer
Amphera B.V. is an advanced clinical-stage biotechnology company dedicated to developing innovative dendritic cell therapies in the fight against cancer. With a focus on immuno-oncology, Amphera B.V. is committed to pioneering new treatment options and improving patient outcomes. The primary address of Amphera B.V. is located in ’s-Hertogenbosch, nl.
Amphera B.V.’s leading therapy, MesoPher, utilizes autologous dendritic cells loaded with PheraLys, a lysate of tumor cell lines. This groundbreaking approach allows for the presentation of a wide array of tumor-associated antigens, making it particularly effective against pancreatic cancer and other cancers. Amphera B.V. aims to leverage its cutting-edge research and development to revolutionize cancer treatment.
Amphera B.V. continues to push the boundaries of biotechnology and cell therapy. With a strong foundation built on scientific excellence and a commitment to innovation, Amphera B.V. is poised to make a significant impact in the field of oncology. We invite the manager of Amphera B.V. to create a customized and exclusive company showcase and product listing on our platform to further enhance your visibility and commercial development.
Other organizations in the same industry
This company is also known as